New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congress
Swedish Orphan Biovitrum AB (publ) (Sobi ®) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today reported new analyses of phase 3 studies that reinforce the robust efficacy and safety profile of Aspaveli®/Empaveli® (pegcetacoplan) for paroxysmal nocturnal haemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with Aspaveli/Empaveli resulted in meaningful improvements in quality of life for treatment-naïve patients and